1. Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta‐analysis of randomized clinical trials
   Shoutao Dang et al, 2023, Cancer Medicine CrossRef
2. Agent-Based Modeling of Virtual Tumors Reveals the Critical Influence of Microenvironmental Complexity on Immunotherapy Efficacy
   Yixuan Wang et al, 2024, Cancers CrossRef
3. Safety and feasibility of minimally invasive gastrectomy after neoadjuvant immunotherapy for locally advanced gastric cancer: a propensity score-matched analysis in China
   Hao Cui et al, 2023, Gastroenterology Report CrossRef
4. Induction Therapy of Tislelizumab Combined with Cisplatin and 5-Fluorouracil and Subsequent Conversion Surgery in Patients with Unresectable Advanced Esophageal Squamous Cell Carcinoma: A Phase 2, Single Center Study
   Tongpeng Xu et al, 2024, Annals of Surgical Oncology CrossRef
5. ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma
   Domenico Mallardo et al, 2024, International Journal of Molecular Sciences CrossRef
6. Engineered biological nanoparticles as nanotherapeutics for tumor immunomodulation
   Juwita N. Rahmat et al, 2024, Chemical Society Reviews CrossRef
7. Pathological examination of factors involved in PD-L1 expression in patients with oral tongue squamous cell carcinoma
   Yu Koyama et al, 2024, Maxillofacial Plastic and Reconstructive Surgery CrossRef
8. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study
   Margherita Rimini et al, 2024, Targeted Oncology CrossRef
9. Structure-Guided Discovery of PD-1/PD-L1 Interaction Inhibitors: Peptide Design, Screening, and Optimization via Computation-Aided Phage Display Engineering
   Tien-Sheng Tseng et al, 2024, Journal of Chemical Information and Modeling CrossRef
10. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review
    Carly C Barron et al, 2023, Journal for ImmunoTherapy of Cancer CrossRef
11. Non‑coding RNA: A promising diagnostic biomarker and therapeutic target for esophageal squamous cell carcinoma (Review)
    Longze Zhang et al, 2024, Oncology Letters CrossRef
12. Programmed death receptor-1/programmed death-ligand 1 inhibitors: Clinical progress and biomarker exploration in gastric cancer
    Jin Shi et al, 2024, Heliyon CrossRef